RNA interference (RNAi) is a powerful tool to study gene function in cultured cells. Transfected cell microarrays in principle allow high-throughput phenotypic analysis after gene knockdown by microscopy. But bottlenecks in imaging and data analysis have limited such high-content screens to endpoint assays in fixed cells and determination of global parameters such as viability. Here we have overcome these limitations and developed an automated platform for high-content RNAi screening by time-lapse fluorescence microscopy of live HeLa cells expressing histone-GFP to report on chromosome segregation and structure. We automated all steps, including printing transfection-ready small interfering RNA (siRNA) microarrays, fluorescence imaging and computational phenotyping of digital images, in a high-throughput workflow. We validated this method in a pilot screen assaying cell division and delivered a sensitive, time-resolved phenoprint for each of the 49 endogenous genes we suppressed. This modular platform is scalable and makes the power of time-lapse microscopy available for genome-wide RNAi screens.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $20.17 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We thank S. Narumiya (Kyoto University, Kyoto) and T. Hirota (Institute of Molecular Pathology; IMP; Vienna) for HeLa 'Kyoto' cells; W. Huber (European Bioinformatics Institute; EBI; Hinxton) for advice on statistical analysis of kinetic data; O. Gruss (Zentrum für Molekulare Biologie Heidelberg; ZNBH; Heidelberg) for TPX2 antibody; J.-M. Peters (IMP; Vienna) for RPE cells; I. Hoffmann (Deutsches Krebsforschungszentrum; DKFZ; Heidelberg) for U2OS cells; H. Runz (Univ. Heidelberg) for primary human fibroblasts; Chroma Inc. for providing customized emission filter sets free of charge; EMBL's IT Services group (B. Kindler, M. Hemberger, R. Lück) for support; Olympus Biosystems, Hamilton and Bio-Rad for continuous support; Cenix BioScience GmbH for siRNA design and for providing the A549 cells; and Ambion Europe, Ltd. for providing siRNAs for validation. This project was funded by grants to J.E. within the MitoCheck consortium by the European Commission (FP6-503464) as well as in part by the Federal Ministry of Education and Research (BMBF) in the framework of the National Genome Research Network (NGFN) (NGFN-2 SMP-RNAi, FKZ01GR0403 to J.E. and NGFN-2 SMP-Cell FKZ01GR0423, NGFN-1 FKZ01GR0101, FKZ01KW0013 to R.P.).
siRNA INCENP - Segregation problem leading to multinucleated cells
siRNA SYNE2 - Metaphase alignment problem followed by segregation followed by apoptosis
siRNA PLK1 - Prometaphase arrest followed by apoptosis
siRNA CDC16 - Metaphase alignment problems followed by apoptosis
siRNA NUP107 - Metaphase alignment problems followed by apoptosis
siRNA NUMA1 - Apoptosis
About this article
Scientific Reports (2017)